1,681 reports of this reaction
1.9% of all AZITHROMYCIN MONOHYDRATE reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for AZITHROMYCIN MONOHYDRATE, manufactured by Aurobindo Pharma Limited. There are 1,681 FDA adverse event reports linking AZITHROMYCIN MONOHYDRATE to HEADACHE. This represents approximately 1.9% of all 89,541 adverse event reports for this drug.
Patients taking AZITHROMYCIN MONOHYDRATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for AZITHROMYCIN MONOHYDRATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for AZITHROMYCIN MONOHYDRATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,681 FDA reports for AZITHROMYCIN MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 1.9% of all adverse event reports for AZITHROMYCIN MONOHYDRATE, making it a notable side effect.
If you experience headache while taking AZITHROMYCIN MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.